EXCLUSIVE: Matinas Bio CEO, Jerry Jabbour Now Interviewing On Benzinga Live YouTube TV
Click To Tune In Here... https://www.youtube.com/watch?v=QZrI941gNoE
Here’s Why Matinas BioPharma Shares Are Rising
Matinas BioPharma Holdings Inc (NASDAQ: MTNB) shares are trading higher by 10.4% at $0.86 after the company and BioNTech announced an exclusive research collaboration to evaluate novel delivery technology for mRNA-based vaccines.
BioNTech And Matinas BioPharma Announce Exclusive Research Collaboration To Evaluate Novel Delivery Technology For mRNA-based Vaccines; Matinas To Receive Upfront Access Fee
Exclusive collaboration combines BioNTech's mRNA vaccine development expertise and Matinas' Lipid Nanocrystal (LNC) Delivery Platform Technology to advance novel formulations for mRNA vaccines, including a
Matinas BioPharma: Q4 Earnings Insights
Matinas BioPharma Hldgs (AMEX:MTNB) reported its Q4 earnings results on Tuesday, March 8, 2022 at 06:15 AM.
Here's what investors need to know about the announcement.
Earnings Scheduled For March 8, 2022
Companies Reporting Before The Bell
• Babcock & Wilcox (NYSE:BW) is likely to report quarterly earnings at $0.10 per share on revenue of $196.62 million.
The Week Ahead In Biotech (March 6-12): Quiet Week On Tap With Earnings Season Reaching It Final Leg
Biotech stocks reversed course in the week ending March 4, as the Ukrainian crisis weighed down on the broader market as well as the sector. The iShares Biotechnology ETF (NASDAQ: IBB) retreated in four out of five sessions of the week.
22 Stocks Moving in Wednesday’s Pre-Market Session
Gainers
Daré Bioscience, Inc. (NASDAQ: DARE) rose 45.2% to $3.08 in pre-market trading after the company reported the FDA approval of XACIATO Vaginal Gel as a treatment for bacterial vaginosis.
Watching Shares Of Matinas BioPharma; Traders Circulate PennyStocks.com Article ‘5 Penny Stocks To Buy According To Analysts With Targets Up To 156%’
https://pennystocks.com/featured/2021/11/16/5-penny-stocks-to-buy-analysts-targets-up-159
Matinas BioPharma Hldgs Q3 EPS $(0.03) Misses $(0.02) Estimate
Matinas BioPharma Hldgs (AMEX:MTNB) reported quarterly losses of $(0.03) per share which missed the analyst consensus estimate of $(0.02) by 50 percent. This is unchanged from the same period last year.
Earnings Scheduled For November 8, 2021
Companies Reporting Before The Bell
• Privia Health Group (NASDAQ:PRVA) is projected to report quarterly loss at $0.11 per share on revenue of $215.14 million.